Boehringer Ingelheim and Ashoka announce a global partnership for "Making More Health"

Boehringer IngelheimBoehringer Ingelheim and Ashoka will launch a three-year global initiative to improve health in communities around the world.The "Making More Health" initiative will promote healthy individuals, families and communities by identifying and supporting the most promising solutions to challenge health problems.

The partnership includes support for a series of programs aimed at identifying innovative health solutions, including the election of 50 leading social entrepreneurs (elected as "Ashoka Fellows") whose ideas are driving cutting-edge systemic solutions in the field of health. In addition, two web-based changemakers competitions will open an invitation to the public to submit new ideas on how to improve health in underserved communities. "Making More Health" will also focus on the next generation of changemakers through a youth venture program to engage young people in designing health solutions for their communities.

Boehringer Ingelheim will support "Making More Health" by engaging its 42,000 employees worldwide in various capacities to help spread an understanding and appreciation of social entrepreneurship and health innovation within their own communities.

Boehringer Ingelheim will support "Making More Health" by engaging its 42,000 employees worldwide in various capacities to help spread an understanding and appreciation of social entrepreneurship and health innovation within their own communities.

"Making More Health brings together two organizations committed to finding innovative people and ideas to help shape the future of the health sector," said Professor Dr Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim. "Through this partnership we will bring forth meaningful and sustainable solutions that can achieve individual and family well-being in communities around the globe."

Ashoka's Chair, Bill Drayton, commented: "Some parts of how the world deals with health are highly creative, most especially the development of new pharmaceuticals, an area where Boehringer Ingelheim has made contribution after contribution for 125 years. Much of the rest of the system, however, has fallen way behind the need. The Making More Health partnership creates a global and business/social alliance led by top entrepreneurs and open to all that we believe will bring big changes to the entire system."

To date, "Making More Health" has supported four leading Ashoka social entrepreneurs in the health sector, including Rebecca Onie, founder of Health Leads in the United States; Frank Hoffmann, founder of Discovering Hands in Germany; Guillaume Bapst, founder of ANDES in France; and Luh Ketut Suryani, founder of the Suryani Institute for Mental Health in Indonesia.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

About Ashoka
Ashoka is the global association of the world's leading social entrepreneurs—men and women with system changing solutions for the world's most urgent social problems. Since 1981, Ashoka has helped launch over nearly 3000 leading social entrepreneurs as Ashoka Fellows, providing them with living stipends, professional support, and access to a global network of peers in 70 countries. Ashoka is known around the world for launching the field of social entrepreneurship and its current work in creating an "Everyone a Changemaker" world encouraging innovation and problem-solving from all.

Most Popular Now

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

Nucala (mepolizumab) gains FDA approval for two ne…

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjec...

Jeff Settleman, Ph.D., joins Pfizer to lead Oncolo…

Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading al...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Full data from CAROLINA® outcome trial support lon…

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardio...

Cleveland researchers test novel gene therapy for …

A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case Comprehensive Cancer Center is showing promising results, garnering funding...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Bristol-Myers Squibb announces post-closing leader…

Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with ...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Prescription drug costs steadily soar, yet price t…

After reviewing tens of millions of insurance claims for the country’s 49 most popular brand-name prescription drugs, a team from Scripps Research Translational Institute...